Program - FRIDAY, MAY 12

Print
Please click on the relevant day to view the applicable detailed program.

Friday, May 12
FRIDAY 12 MAY, 2017
 
Hall A
08:00-09:00
SESSION 8 | Present and Future
08:00-08:05  Chairperson: Ehud Grossman, Israel and Zhao Zhigang, China
08:05-08:25 
Treatment of T2DM: The Present and the Future: Ralph DeFronzo, USA
08:25-08:45 
Present and Future of Diabetes in China: Ning Guang, China
08:45-09:00 
Discussion
 
Hall B
08:00-09:00
SESSION 9 | Diabetes in Adolescents
08:00-08:05  Chairpersons: Peng Yongde, China
08:05-08:25  Pathogenesis of childhood - adolescent obesity and DM - environmental toxins or just obesity? Yang Tao, China
08:25-08:45 
Treatments for DM in adolescents: Paolo Pozzilli, Italy
08:45-09:00 
Discussion
 
Hall C
08:00-09:00
SESSION 10 | T1DM
08:00-08:05  Chaiperson: Teng Weiping, China
08:05-08:20 
Beyond insulin therapy (GLP1, SGLT2): Ji Linong, China
08:20-08:35
Novel therapies (stem cells BM tx): Zhu Dalong, China
08:35-08:50 
Advances in technology (closed loop etc): Eytan Roitman, Israel
08:50-09:00 
Discussion
 
Hall A
09:00-10:30
SESSION 11 | New Developments in Endocrine Hypertension
09:00-09:05  Chairperson: Chen Bing, China
09:05-09:30  Aberrant regulation of aldosterone in primary aldosteronism: Andre Lacroix, Canada
  Should genetic evaluation be routinely performed in patients with phechromocytoma/paraganglioma?
09:30-09:50 Yes: Su Tingwei, China 
09:50-10:10  No: Alon Grossman, Israel
10:10-10:30  Discussion
 
Hall B
09:00-10:30 SESSION 12 | Guideline in Diabetes Care
09:00-09:05  Chairperson: Ralph DeFronzo, USA
09:05-09:30  Metformin - revisiting its role as 1st line therapy: Ralph DeFronzo, USA
09:30-09:50  Real world data vs. clinical trial data: Itamar Raz, Israel
09:50-10:10  Guidelines or personalized therapy: Ji Qiuhe, Discussion
10:10-10:30  Discussion
  Plenary Hall
09:00-10:30 Session 13 | Pitch Presentations 
10:30-11:00
Technical Break
 
Hall A
11:00-12:00
Industry-Sponsored Symposium J Sponsored by 3Sbio
  Chairperson: Wang Weiqing, China
  Clinical practice of combination therapy of Exenatide and Insulin Glargine in type 2 diabetes patients: Itamar Raz, Israel
  Discussion 
  Hall B
11:00-12:00 Industry-Sponsored Symposium K Sponsored by Merck
  Chairperson: Ji Qiuhe, China
  Initial treatment strategies in newly diagnosed type 2 diabetes: Li Yanbing, China
  Insights of diabetic microvascular complication (DMVC) and its management: Peng Yongde, China
  Hall C
11:00-11:30 Industry-Sponsored Symposium L a | Innovative Glucose Monitoring Solution - FreeStyle Libre & Ambulatory Glucose Profile Sponsored by Abbot
  Chairperson: Su Qing, China
  FreeStyle Libre and AGP introduction: Zhou Ligang, China
11:30-12:00 Industry-Sponsored Symposium L b Sponsored by Novartis
  Chairperson: Ning Guang
12:00-12:15 Lunch Box Pick Up
 
Hall A
12:15-13:15
Industry-Sponsored Symposium M Sponsored by AstraZeneca
  Chairpersons: Ning Guang, China and Itamar Raz, Israel
  The role of kidney in glucose homeostasis - Implication for treatment of T2DM: Ralph DeFronzo, USA
  Efficacy, safety of dapagliflozin - China evidence: Ji Linong, Chins
  SGLT-2 inhibitor in clinical practices - Asian data and experience sharing: Karen Lam, Hong Kong
13:15-13:45
Technical Break
 
Hall A
13:45-14:45
SESSION 14 | Prevention of Diabetes
13:45-13:50 
Chairperson: Zhang Junqing, China
13:50-14:05
Why do tranlational studies show such limited benefits? Itamar Raz, Israel
14:05-14:20 How to identify high risk population - risk scores and stratification: Bi Yufang, China
14:20-14:35 Monogenic diabetes: Jia Weiping, China
14:35-14:45 Discussion
 
Hall B
13:45-14:45
SESSION 15 | Drug Induced Hypertension – Frequently Overlooked Hypertension
13:45-13:50  Chairperson: Wang Weiqing, China
13:50-14:05
Anti VEGF and blood pressure: Alon Grossman, Israel
14:05-14:20 
Cab we use NSAIDs in hypertensive patients: Ehud Grossman, Israel
14:20-14:45  Discussion 
 
Hall C
13:45-14:45
SESSION 16 | Insulin
13:45-13:50  Chairperson: Qin Guijun, China
13:50-14:05
Intensive insulin therapy at diabetes onset or basal + meds - what is the evidence?  Li Yanbing, China
14:05-14:20
Combinations of insulin + meds - fixed dose/ regular pre-mixed insulin - does it still have a role (ryzofeg?): Paolo Pozzilli, Italy
14:20-14:45 
Discussion
14:45-15:00  Technical Break
 
Plenary Hall
15:00-17:00
SESSION 17 | Digital Therapy - Debate and Consensus
15:00-15:05 Chairperson: Itamar Raz, Israel and Eli Tzfoni, Israel
15:05-15:30 
Big data, cloud and machine learning: Dov Moran, Israel
15:30-15:55 SBGM vs CGM and digital treatment support: Eytan Roitman, Israel
15:55-16:20 Legal challenges for telemedical companies in Cina: Mark Zhang and Cecilia Lou China (King & Wood Mallesons)
16:20-17:00
Discussion